Gadolinium-based contrast: an alternative contrast agent for endovascular interventions

Area of Science:

• Radiology
• Medical Imaging
• Interventional Radiology

Background:

• Gadoterate meglumine (Gd-DOTA) is a radiocontrast substance utilized in magnetic resonance imaging (MRI).
• Gd-DOTA exhibits a low incidence of adverse drug reactions, prompting its evaluation as an alternative contrast medium.

Purpose of the Study:

• To assess the safety and efficacy of gadoterate meglumine (Gd-DOTA) as an alternative contrast agent in diagnostic and therapeutic endovascular procedures.
• To determine the suitability of Gd-DOTA in situations where iodine-based contrast agents are contraindicated.

Main Methods:

• Twenty-three endovascular procedures were conducted using undiluted gadoterate meglumine (Gd-DOTA) at a concentration of 376.9 mg/mL (Dotarem).
• Digital subtraction techniques were employed for imaging.
• Dosages ranged from 30-90 mL.
• Serum creatinine levels were monitored pre-procedure and at 24 and 48 hours post-procedure to assess renal function.

Main Results:

• The study involved 23 procedures using Gd-DOTA.
• Serum creatinine levels were tracked to evaluate kidney function post-administration.
• No specific adverse events related to Gd-DOTA were detailed in the abstract, but its use was considered based on its known low reaction rate.

Conclusions:

• Gadoterate meglumine (Gd-DOTA) can be considered a viable alternative contrast agent for specific endovascular procedures.
• Its use is particularly recommended when iodine-based contrast agents pose a contraindication due to potential adverse reactions.